review
research
focu
ddt
vol
august
advanc
bioinformat
protein
model
algorithm
addit
enorm
increas
experiment
protein
structur
inform
aid
gener
databas
compris
homolog
model
signific
portion
known
genom
protein
sequenc
current
structur
inform
gener
known
protein
howev
consider
controversi
concern
real
valu
homolog
model
drug
design
review
provid
overview
latest
develop
area
includ
select
exampl
success
applic
homolog
model
techniqu
pharmaceut
relev
question
addit
strength
limit
applic
homolog
model
phase
drug
discoveri
process
discuss
wwwdrugdiscoverytodaycom
w
protein
unknown
structur
fold
assign
sequencestructur
align
model
build
sidechain
loop
model
refin
model
assess
see
front
matter
elsevi
ltd
right
reserv
pii
major
drug
avail
today
discov
either
chanc
observ
screen
synthet
natur
product
librari
chemic
modif
lead
compound
trialanderror
basi
typic
led
compound
improv
potenc
select
bioavail
reduc
toxic
howev
approach
laborand
timeintens
research
pharmaceut
industri
constantli
develop
method
view
increas
effici
drug
discoveri
process
two
direct
evolv
effort
random
approach
involv
develop
ht
assay
test
larg
number
compound
combinatori
chemistri
use
satisfi
need
extens
compound
librari
ration
protein
structurebas
approach
reli
iter
procedur
initi
determin
structur
target
protein
follow
predict
hypothet
ligand
target
protein
molecular
model
subsequ
chemic
synthesi
biolog
test
specif
compound
structurebas
drug
design
cycl
ration
approach
sever
limit
target
protein
amen
structur
determin
although
protein
data
bank
pdb
http
wwwrcsborgpdb
grow
rapidli
new
entri
daili
structur
known
protein
yet
experiment
character
howev
advanc
sequenc
comparison
fold
recognit
proteinmodel
algorithm
enabl
partial
closur
socal
sequencestructur
gap
extens
experiment
protein
structur
inform
homolog
protein
qualiti
homolog
model
thu
applic
exampl
drug
discoveri
predominantli
depend
sequenc
similar
protein
known
structur
templat
protein
model
target
despit
numer
uncertainti
associ
homolog
model
recent
research
shown
approach
use
signific
advantag
identif
valid
drug
target
well
identif
optim
lead
compound
review
focu
applic
homolog
model
drug
discoveri
process
homolog
compar
model
use
experiment
determin
protein
structur
predict
conform
anoth
protein
similar
amino
acid
sequenc
method
reli
observ
natur
structur
conform
protein
highli
conserv
amino
acid
sequenc
small
medium
chang
sequenc
typic
result
small
chang
structur
gener
process
homolog
model
involv
four
step
fold
assign
sequenc
align
model
build
model
refin
figur
fold
assign
process
identifi
protein
known
structur
templat
structur
relat
polypeptid
sequenc
unknown
structur
target
sequenc
mistaken
drug
target
next
sequenc
databas
protein
known
structur
eg
pdbsequenc
databas
search
target
sequenc
use
sequenc
similar
search
algorithm
thread
techniqu
follow
identif
distinct
correl
target
protein
protein
known
structur
two
protein
sequenc
align
identifi
optimum
correl
residu
templat
target
sequenc
next
stage
homolog
model
process
modelbuild
phase
model
target
protein
construct
substitut
amino
acid
structur
templat
protein
insert
andor
delet
amino
acid
accord
sequenc
align
final
construct
model
check
regard
conform
aspect
correct
energi
minim
use
forcefield
approach
sever
improv
modif
gener
homolog
model
strategi
develop
appli
predict
protein
structur
subject
avail
structur
predict
method
blind
test
communitywid
experi
critic
assess
techniqu
protein
structur
predict
casp
perform
result
present
publish
result
current
stateoftheart
protein
structur
predict
establish
progress
made
document
area
futur
effort
might
product
concentr
highlight
homolog
model
techniqu
depend
avail
highresolut
experiment
protein
structur
data
develop
effect
protein
express
system
major
technolog
advanc
instrument
use
structur
determin
xray
crystallographi
nmr
spectroscopi
contribut
exponenti
growth
number
experiment
protein
structur
may
pdb
contain
experiment
protein
structur
differ
protein
protein
less
sequenc
ident
recent
analysi
protein
chain
pdb
show
protein
group
protein
famili
ddt
vol
august
review
research
focu
wwwdrugdiscoverytodaycom
figur
step
involv
predict
protein
structur
homolog
model
structur
model
bacteri
transcript
repressor
copr
shown
although
model
base
lowsequ
ident
copr
repressor
sever
experiment
method
support
homolog
model
reproduc
permiss
ref
abbrevi
copr
plasmid
copi
control
protein
target
sequenc
homolog
structur
homolog
structur
templat
structur
templat
structur
compris
uniqu
protein
fold
updat
found
http
scopmrclmbcamacuk
major
structur
pdb
determin
xray
crystallographi
structur
character
nmr
spectroscopi
pdb
databas
encompass
experiment
inform
extens
array
ligand
small
organ
molecul
ion
bound
differ
bind
site
analyz
use
program
includ
relibas
http
relibaseebiacuk
ligbas
http
altocompbioucsfeduligbas
pdbsum
http
wwwbiochemuclacukbsmpdbsum
although
experiment
structur
databas
grow
rapidli
still
substanti
gap
number
known
annot
sequenc
uniqu
sequenc
swissprottrembl
http
wwwexpasyorg
sprot
august
known
protein
structur
significantli
differ
protein
consid
omit
mutein
artifici
protein
multipl
structur
determin
protein
eg
hivproteas
carbon
anhydras
ii
less
structur
known
protein
sequenc
elucid
sequencestructur
gap
partli
fill
homolog
model
exampl
queryabl
databas
modbas
http
altocompbio
ucsfedumodbasecgiindexcgi
provid
access
enorm
number
annot
compar
protein
structur
model
program
psiblast
use
assign
protein
fold
uniqu
sequenc
entri
swissprottrembl
sequenc
compar
model
averag
model
size
amino
acid
could
built
use
program
model
thu
august
structur
model
protein
access
via
internet
model
predict
least
c
atom
superimpos
within
correct
posit
inform
bind
site
ligand
retriev
databas
use
ligbas
howev
major
model
built
low
sequenc
ident
realiz
level
accuraci
case
suffici
detail
structurebas
ligand
design
swissmodel
repositori
http
swissmodelexpasi
orgrepositori
also
databas
annot
compar
protein
structur
model
gener
use
fulli
autom
homologymodel
pipelin
swissmodel
august
databas
contain
model
differ
protein
sequenc
entri
swissprottrembl
databas
sequenc
averag
model
size
amino
acid
research
eidogen
http
wwweidogencom
creat
databas
system
call
target
informat
current
includ
homolog
model
protein
homolog
model
human
protein
sequenc
result
construct
model
differ
sequenc
thu
put
known
ligand
bind
pocket
detect
analyz
compar
result
data
use
support
target
priorit
lead
discoveri
andor
optim
procedur
accelri
http
wwwaccelryscom
produc
discoveri
studio
ds
complet
oracl
base
protein
ligand
structur
data
manag
solut
current
ds
contain
homolog
model
automat
gener
sequenc
protein
differ
genom
conjunct
homolog
model
cengent
therapeut
http
wwwcengentcom
offer
dynam
structur
inform
gener
molecular
dynam
simul
human
drug
target
protein
structur
inform
use
target
priorit
virtual
screen
qualiti
homolog
model
depend
level
sequenc
ident
protein
known
structur
protein
model
sequenc
ident
greater
homolog
assum
two
protein
probabl
common
ancestor
therefor
evolutionarili
relat
like
share
common
structur
case
pairwis
multipl
sequenc
align
algorithm
reliabl
use
gener
homolog
model
figur
sequenc
ident
structur
model
becom
specul
could
lead
mislead
conclus
sequenc
ident
convent
align
method
suffici
reliabl
sophist
profilebas
method
capabl
recogn
homolog
predict
fold
region
low
sequenc
ident
thread
method
often
appli
protein
model
built
low
sequenc
ident
use
assign
protein
function
direct
mutagenesi
experi
figur
model
sequenc
ident
could
facilit
structurebas
predict
target
drugabl
design
mutagenesi
experi
design
vitro
test
assay
figur
sequenc
ident
greater
result
model
frequent
suffici
qualiti
use
predict
detail
proteinligand
interact
structurebas
drug
design
predict
prefer
site
metabol
small
molecul
figur
numer
applic
protein
structur
inform
henc
homolog
model
variou
stage
drug
discoveri
process
spectacular
success
clearli
protein
structur
inform
help
identifi
optim
compound
subsequ
progress
clinic
trial
drug
market
applic
homolog
model
impact
target
identif
andor
valid
lead
identif
lead
optim
review
figur
clear
minut
fraction
entir
proteom
affect
druglik
preferenti
oral
bioavail
small
molecul
base
total
number
known
gene
diseasemodifi
gene
drugabl
protein
number
drug
target
protein
human
estim
small
molecul
set
properti
establish
differenti
drug
compound
properti
use
identifi
compound
exampl
poor
oral
absorpt
properti
drug
molecul
correspond
target
protein
highli
complementari
suggest
rule
distinguish
good
target
protein
other
deduc
deep
lipophil
pocket
compris
distinct
polar
interact
site
clearli
superior
shallow
highli
charg
protein
surfac
region
inhibit
proteinprotein
interfac
valuabl
therapeut
principl
recent
shown
inhibitor
doubl
minut
clone
interact
bind
site
inhibitor
distinct
lipophil
pocket
normal
interact
surfac
patch
tumor
suppressor
transactiv
domain
advanc
rapid
detect
descript
analysi
ligandbind
pocket
togeth
avail
million
homolog
model
open
new
possibl
priorit
protein
regard
drugabl
pharmaceut
industri
structur
aspect
increasingli
implement
addit
decis
criteria
drugabl
potenti
drug
target
compani
inpharmatica
http
wwwinpharmaticacom
develop
integr
suit
informaticsbas
discoveri
technolog
contain
softwar
tool
structurebas
assess
target
drugabl
design
sitedirect
mutant
protein
one
import
option
applic
homolog
model
target
valid
introduc
point
mutat
subsequ
studi
effect
vitro
vivo
common
approach
molecular
biolog
strategi
enabl
identif
amino
acid
function
relationship
target
templat
sequenc
ident
inform
content
result
homolog
model
arrow
indic
method
use
detect
sequenc
similar
target
templat
sequenc
applic
homolog
model
drug
discoveri
list
right
higher
sequenc
ident
accur
result
structur
inform
homolog
model
built
sequenc
ident
frequent
use
drug
design
purpos
superimposit
xray
crystal
structur
ligandbind
domain
member
nuclear
receptor
famili
shown
left
xray
structur
illustr
increas
structur
deviat
decreas
sequenc
ident
pr
red
gr
green
blue
cyan
sequenc
ident
pr
gr
pr
pr
abbrevi
estrogen
receptor
gr
glucocorticoid
receptor
pr
progesteron
receptor
thyroid
receptor
structur
import
protein
investig
ultim
contribut
biolog
knowledg
exampl
potenti
target
protein
typic
amino
acid
modifi
studi
select
basi
sequenc
align
focus
conserv
residu
howev
least
structur
inform
avail
select
amino
acid
mutat
much
precis
success
approach
even
power
appli
conjunct
pharmacolog
activ
compound
sitedirect
mutant
target
protein
made
render
target
sensit
exist
pharmacolog
agent
base
homolog
model
member
mitogenactiv
protein
map
kinas
famili
mutat
make
sensit
kinas
inhibitor
pyridinyl
imidazol
class
enabl
use
compound
broader
target
valid
studi
one
attract
way
valid
target
protein
administ
pharmacolog
activ
compound
select
act
protein
studi
effect
relev
anim
model
similar
strategi
describ
term
chemogenom
recent
shown
possibl
design
small
molecul
base
homolog
model
use
compound
tool
studi
physiolog
role
respect
target
protein
particular
drug
eight
year
discoveri
estrogen
receptor
distinct
role
two
er
isotyp
mediat
physiolog
respons
estrogen
complet
understood
although
knockout
anim
experi
provid
insight
estrogen
signal
addit
inform
function
impart
applic
isotyp
select
er
agonist
base
crystal
structur
domain
lbd
homolog
model
sequenc
ident
hillisch
et
al
design
steroid
ligand
exploit
differ
size
flexibl
two
ligandbind
caviti
figur
compound
predict
bind
preferenti
either
synthes
test
vitro
approach
led
directli
highli
er
isotypeselect
ligand
also
highli
potent
unravel
physiolog
role
two
receptor
vivo
experi
rat
conduct
use
agonist
parallel
natur
ligand
er
agonist
shown
respons
known
estrogen
effect
eg
induct
uterin
growth
boneprotect
addit
pituitari
eg
reduct
lutein
hormon
plasma
level
liver
eg
increas
angiotensin
plasma
level
effect
howev
agonist
distinct
effect
ovari
exampl
stimul
earli
folliculogenesi
possibl
present
clinician
new
option
tailor
classic
ovarian
stimul
protocol
comparison
homolog
model
xray
crystal
structur
complex
genistein
reveal
homolog
model
rootmeansquar
deviat
rmsd
backbon
atom
consid
helix
xray
crystal
structur
confirm
presenc
essenti
interact
ligand
reveal
least
case
new
aspect
design
agonist
cover
homolog
model
studi
show
possibl
design
highli
select
compound
structur
inform
relev
homolog
target
avail
ddt
vol
august
review
research
focu
wwwdrugdiscoverytodaycom
figur
applic
homolog
model
drug
discoveri
process
enorm
amount
protein
structur
inform
current
avail
could
support
lead
compound
identif
optim
could
also
contribut
target
identif
valid
reproduc
permiss
numer
exampl
protein
homolog
model
support
discoveri
optim
lead
compound
respect
potenc
select
current
structur
known
differ
human
protein
kinas
character
xray
crystallographi
homolog
modelbas
drug
design
appli
epiderm
growth
factorreceptor
tyrosin
kinas
protein
bruton
tyrosin
kinas
janu
kinas
human
aurora
kinas
use
xray
crystal
structur
cyclindepend
kinas
honma
et
al
gener
homolog
model
model
guid
design
highli
potent
select
inhibitor
target
toward
atp
bind
pocket
diarylurea
class
compound
subsequ
synthes
test
vitro
inhibit
assay
potent
compound
ic
nm
predict
bind
mode
lead
compound
verifi
cocrystal
vangrevelingh
et
al
identifi
inhibitor
use
homolog
model
protein
highthroughput
dock
siedlecki
et
al
demonstr
util
homolog
model
predict
pharmacolog
activ
compound
alter
dna
methyl
pattern
play
import
role
tumorigenesi
therefor
inhibitor
dna
methyltransferas
protein
repres
major
dna
methyltransferas
activ
human
cell
desir
known
inhibitor
class
dock
activ
site
homolog
model
led
design
deriv
act
highli
potent
inhibitor
dna
methyl
vitro
thrombinactivat
fibrinolysi
inhibitor
tafi
import
regul
fibrinolysi
inhibitor
enzym
potenti
use
antithrombot
thrombolyt
therapi
base
homolog
model
tafi
sequenc
ident
carboxypeptidas
b
appropri
substitut
imidazol
acet
acid
design
subsequ
found
potent
select
inhibitor
activ
tafi
homolog
model
voltageg
k
channel
k
v
ca
activ
channel
ik
ca
use
design
select
ik
ca
inhibitor
base
polypeptid
toxin
charybdotoxin
comparison
two
model
reveal
uniqu
cluster
neg
charg
residu
turret
k
v
present
ik
ca
exploit
differ
homolog
model
use
design
novel
analog
synthes
test
research
demonstr
novel
compound
block
ik
ca
activ
higher
affin
k
v
b
comparison
two
isotyp
estrogen
receptor
homolog
model
blue
green
ligandbind
pocket
shown
complex
natur
ligand
er
bind
highli
potent
select
agonist
model
ligandbind
nich
depict
right
reproduc
permiss
ref
c
model
antiprogestin
ru
mifepriston
bound
hpr
singl
amino
acid
mutat
render
compound
inact
cpr
hamster
pr
steric
clash
ru
cpr
shown
right
side
abbrevi
er
estrogen
receptor
human
estrogen
receptor
cpr
chicken
progesteron
receptor
hpr
human
progesteron
receptor
pr
progesteron
receptor
rba
rel
bind
affin
key
proteinas
pro
pro
new
coronaviru
cov
caus
sever
acut
respiratori
syndrom
sar
outbreak
sarscov
anoth
exampl
success
homolog
model
build
case
success
defin
abil
use
model
propos
inhibitor
signific
affin
target
enzym
xray
crystal
structur
pro
transmiss
gastroenter
viru
tgev
porcin
coronaviru
human
coronaviru
character
proteinas
sequenc
ident
respect
key
proteinas
sarscov
follow
public
genom
sequenc
new
viru
first
internet
week
later
print
level
sequenc
ident
proteinas
enabl
anand
et
al
construct
homolog
model
pro
human
cov
howev
homolog
model
gener
insuffici
design
inhibitor
reason
confid
establish
structur
basi
interact
polypeptid
substrat
pro
anand
cowork
synthes
substrateanalog
hexapeptidyl
chloromethylketon
inhibitor
complex
tgev
pro
xray
crystal
structur
complex
determin
reveal
expect
chloromethylketon
moieti
coval
react
activesit
cystein
residu
proteinas
side
chain
inhibitor
bound
therebi
defin
specif
bind
site
target
enzym
experiment
determin
structur
inhibitortgev
pro
complex
compar
inhibitor
complex
cystein
proteinas
pdb
reveal
surprisingli
similar
inhibitor
bind
mode
complex
human
rhinoviru
type
proteinas
figur
time
late
phase
ii
clinic
trial
drug
treatment
strain
common
cold
caus
human
rhinoviru
comparison
crystal
structur
complex
tgev
pro
complex
hexapeptidyl
chloromethylketon
inhibitor
reveal
littl
similar
two
target
enzym
except
immedi
neighborhood
catalyt
cystein
residu
almost
perfect
match
inhibitor
investig
find
dock
substratebind
site
sarscov
pro
model
without
much
difficulti
although
note
could
potenti
steric
problem
pfluorobenzyl
group
pocket
also
ethylest
moieti
therefor
propos
although
ideal
inhibitor
compound
good
start
point
design
antisar
drug
inde
day
onlin
public
result
sciencexpress
confirm
antisar
activ
vitro
deriv
modifi
residu
sinc
shown
k
valu
lower
rang
rao
et
al
per
commun
crystal
structur
authent
sarscov
key
proteinas
determin
month
later
although
dimer
structur
show
expect
similar
homolog
enzym
tgev
human
cov
interest
differ
detail
particular
one
monom
dimer
observ
inact
conform
thought
result
low
ph
crystal
overal
rmsd
entir
dimer
homolog
model
anand
et
al
ie
residu
exclud
comparison
drop
outlier
carboxi
terminu
exclud
comparison
three
individu
domain
enzym
homolog
model
gener
debe
unpublish
virtual
screen
perform
use
sarscov
pro
model
taken
togeth
find
confirm
homolog
model
often
inadequ
predict
mutual
orient
domain
multidomain
protein
howev
homolog
model
gener
anand
et
al
also
show
reason
model
substratebind
site
serv
develop
use
idea
inhibitor
design
inspir
medicin
chemist
start
synthesi
program
long
structur
target
enzym
experiment
determin
case
gproteincoupl
receptor
gpcr
homologymodel
approach
limit
lack
experiment
determin
structur
low
sequenc
similar
structur
character
respect
pharmacolog
import
target
protein
xray
crystal
structur
one
gpcr
bovin
rhodopsin
determin
structur
complement
bacteriorhodopsin
transmembran
protein
compris
seven
helic
also
relev
model
approach
even
though
protein
gpcr
exampl
homolog
model
gpcr
util
recent
review
highthroughput
dock
appli
verifi
abil
homolog
model
identifi
agonist
glucocorticoid
receptor
agonist
antagonist
retino
acid
receptor
dopamin
muscarin
acetylcholineand
v
vasopressinreceptor
inhibitor
thrombin
identif
thrombin
inhibitor
homolog
model
thrombin
built
retrospect
base
homolog
serin
proteas
sequenc
ident
best
dock
solut
yield
model
deriv
protein
higher
sequenc
ident
recent
perform
dock
studi
protein
activ
site
construct
homolog
model
assess
use
experiment
screen
dataset
factor
viia
sequenc
ident
model
templat
near
bind
site
greater
approxim
fivefold
increas
number
activ
compound
identifi
would
detect
randomli
perform
compar
dock
crystal
structur
applic
homolog
model
design
test
assay
vitro
pharmacolog
character
compound
ht
base
structur
coiledcoil
domain
cjun
model
protein
design
use
affinitytag
protein
incorpor
proteas
cleavag
site
result
kda
recombin
protein
synthes
use
molecularli
defin
uniform
substrat
vitro
detect
iga
endoproteas
activ
enabl
surfac
plasmon
resonancebas
screen
inhibitor
enorm
volum
structur
inform
entir
target
protein
famili
avail
might
also
impact
screen
cascad
mani
drug
discoveri
project
endeavor
identifi
ligand
highli
select
particular
drug
target
select
compound
suppos
superior
compound
typic
lead
fewer
advers
side
effect
eg
inhibitor
howev
import
homolog
target
desir
drug
respect
actual
target
alway
clear
particularli
within
larger
target
protein
famili
sequenc
similar
fulllength
protein
entir
domain
might
alway
repres
target
protein
consid
conserv
ligandbind
pocket
comparison
shape
featur
bind
pocket
within
protein
famili
could
indic
homolog
includ
screen
cascad
socal
counter
screen
structur
inform
current
avail
entir
protein
famili
eg
proteas
kinas
nuclear
receptor
could
contribut
design
select
compound
better
screen
cascad
could
potenti
advanc
design
drug
fewer
side
effect
detail
structur
knowledg
ligandbind
site
target
protein
also
shown
facilit
select
anim
model
ex
vivo
vivo
experi
propos
anim
target
protein
significantli
differ
bind
site
compar
human
ortholog
exclud
pharmacolog
model
mani
promis
compound
show
highpot
human
vitro
assay
reach
clinic
trial
efficaci
could
demonstr
anim
model
singl
amino
acid
differ
human
anim
might
case
suffici
caus
effect
er
select
ligand
describ
hillisch
et
al
shown
homolog
model
vitro
assay
crucial
depend
interact
ligand
substitu
one
particular
amino
acid
differ
figur
ensur
import
interact
present
estrogen
receptor
anim
model
use
character
compound
homolog
model
murin
rat
bovin
built
compar
bind
pocket
human
complet
conserv
amino
acid
within
bind
pocket
human
murin
rat
observ
howev
bovin
show
one
amino
acid
differ
exact
posit
determin
crucial
ligand
select
predict
select
compound
bind
bovin
later
verifi
use
transactiv
experi
unpublish
result
thu
implement
uninterpret
experi
could
avoid
earli
stage
otherwis
attract
bovin
tissu
later
avail
larger
amount
could
exclud
ex
vivo
investig
similarli
inform
structur
progesteron
receptor
pr
use
explain
abolish
bind
progesteron
antagonist
mifepriston
ru
chicken
pr
hamster
pr
singl
point
mutat
human
pr
chicken
pr
prevent
antiprogestin
contain
substitu
eg
ru
bind
chicken
hamster
pr
figur
therefor
exclud
hamster
exampl
pharmacolog
studi
antiprogestin
futur
effect
could
predict
particular
speci
could
exclud
pharmacolog
studi
earli
stage
would
ultim
reduc
attrit
rate
drug
discoveri
process
one
challeng
lead
optim
identifi
compound
show
high
potenc
desir
target
protein
also
adequ
physic
properti
reach
system
circul
resist
metabol
inactiv
specif
time
period
avoid
undesir
pharmacolog
effect
knowledg
structur
protein
involv
process
drugmetabol
enzym
transcript
factor
transport
could
help
design
molecul
interact
nontarget
protein
cytochrom
cyp
extrem
import
class
enzym
involv
phase
oxid
metabol
structur
divers
chemic
hepat
cyp
respons
metabol
known
drug
recent
xray
crystal
structur
three
mammalian
cyp
solv
repres
solid
basi
homolog
model
entir
superfamili
model
gener
use
differ
structur
templat
model
use
explain
predict
probabl
site
metabol
attack
varieti
cyp
substrat
howev
larg
lipophil
highli
flexibl
charact
cyp
bind
caviti
render
pure
silico
approach
toward
predict
occurr
site
small
molecul
metabol
extrem
difficult
protein
structur
inform
combin
pharmacophor
pattern
quantum
mechan
calcul
predict
concern
prefer
site
metabol
within
small
molecul
possibl
regard
aspect
homolog
model
particularli
interest
cyp
caucasian
popul
produc
polymorph
member
cyp
superfamili
result
defici
drug
oxid
lead
sever
side
effect
individu
predict
whether
lead
compound
could
act
substrat
could
help
identifi
problemat
case
earli
drug
discoveri
combin
homolog
model
quantit
sar
approach
abl
predict
cyp
inhibitor
thu
futur
protein
structur
inform
conjunct
highthroughput
dock
pharmacophorebas
method
could
use
decid
compound
potenti
inhibit
particular
cyp
approach
could
facilit
detect
potenti
drugdrug
interact
earli
drug
discoveri
process
measur
could
taken
avoid
interact
cyp
substrat
inhibitor
compound
studi
use
homolog
model
approach
use
recent
investig
cyp
induc
induct
cyp
primarili
mediat
via
activ
liganddepend
transcript
factor
aryl
hydrocarbon
receptor
ahr
famili
constitut
androstan
receptor
car
famili
pregnan
x
receptor
pxr
glucocorticoid
receptor
gr
vitamin
receptor
vdr
famili
principl
silico
predict
drugmetabol
enzym
induct
could
reduc
predict
bind
activ
transcript
factor
eg
ahr
car
howev
recent
xray
structur
analys
pxr
shown
lbd
nuclear
receptor
contain
larg
lipophil
flexibl
bind
pocket
render
pure
silico
structurebas
predict
concern
whether
small
molecul
activ
pxr
difficult
homolog
model
car
member
nuclear
receptor
famili
involv
cyp
induct
recent
describ
model
predict
reason
shape
potenti
ligand
bind
pocket
howev
result
util
model
need
respect
structurebas
predict
advers
health
effect
progress
describ
human
etheragogorel
gene
herg
tetramer
potassium
channel
contribut
phase
three
repolar
heart
muscl
cell
oppos
depolar
ca
influx
plateau
phase
inhibit
protein
result
cardiovascular
toxic
qtprolong
caus
sever
drug
withdrawn
market
therefor
silico
predict
probabl
format
interact
drug
herg
gain
enorm
attent
recent
review
homolog
model
herg
base
xray
crystal
structur
bacteri
kcsa
mthk
channel
alreadi
shed
light
detail
molecular
interact
initi
herg
inhibit
howev
complex
potassium
channel
signifi
detail
xray
structur
analys
protein
openand
closedst
requir
molecular
interact
fulli
understood
predict
implic
predict
cardiotox
numer
exampl
success
applic
homolog
model
drug
discoveri
describ
absenc
experiment
structur
drug
target
protein
homolog
model
support
design
sever
potent
pharmacolog
agent
one
advantag
homolog
model
model
gener
ddt
vol
august
review
research
focu
rel
easili
quickli
furthermor
model
could
support
hypothes
medicin
chemist
gener
biolog
activ
compound
import
earli
conceptu
phase
drug
discoveri
project
design
compound
select
direct
particular
drug
target
protein
one
strength
techniqu
select
compound
even
appli
gain
insight
physiolog
role
novel
drug
target
silico
protein
structurebas
predict
metabol
toxic
small
molecul
particularli
cyp
inhibit
induct
herg
inhibit
current
infanc
predict
capabl
could
limit
classif
howev
complet
experiment
structur
pharmacolog
import
protein
miss
homolog
model
techniqu
provid
one
approach
bridg
gap
inform
becom
avail
